This change is not just a passing trend but a lasting transformation that the industry must embrace for sustained growth and business resilience
Not every patient is a suitable candidate
By the end of 2025, WEGOVY was available in 52 countries worldwide, nearly doubling its global footprint, with additional launches planned for 2026, subject to regulatory approvals
The unique liposome structure allows it to combine effectively with the bodys natural fluids and penetrate its protective membranes, bypassing the digestive system and directly entering the blood stream.* By avoiding the process of digestion, nutrient absorption and utilization is much quicker and more complete.
INSR substrate 1 (IRS1) and 2 (IRS2) are the main targets that intracellularly coordinate insulin action (Thirone et al., 2006
Studies on skin permeation (PMID: 39795193) have investigated liposomal formulations for delivering GHK-Cu to skin tissue, measuring antiaging effects on skin architecture